Summary & Overview
HCPCS Level II J9030: BCG Intravesical Instillation, 1 mg
HCPCS Level II code J9030 denotes the intravesical administration of BCG (bacillus Calmette-Guérin), 1 mg, and is central to bladder cancer intravesical therapy practices nationwide. The code captures drug administration events where BCG is instilled directly into the bladder, typically in outpatient hospital clinics or ambulatory clinic settings. Nationally, accurate reporting of this HCPCS Level II code supports clinical tracking, quality measurement, and payer processing for a commonly used intravesical antineoplastic therapy.
This analysis covers coverage and billing considerations across major payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will find a concise overview of clinical context for use of J9030, common service settings, related procedural and evaluation codes, and operational notes relevant to billing workflows. The publication addresses coding relationships and common modifiers used with drug administration claims, outlines pertinent diagnosis links for intravesical BCG therapy, and provides comparisons to related administration and instillation procedure codes.
Where specific commercial or program-level policy details are unavailable, the publication notes limitations as "Data not available in the input." The content is intended to clarify how J9030 is applied in clinical billing and coding processes and to inform billing, coding, and revenue cycle stakeholders of the code's role in documenting intravesical BCG therapy.
Billing Code Overview
HCPCS Level II code J9030 represents BCG live intravesical instillation, 1 mg, a drug administration service used for intravesical therapy. This code is used to report the instillation of bacillus Calmette-Guérin (BCG) directly into the bladder as a therapeutic agent.
Service type: Drug administration (intravesical therapy)
Typical site of service: Hospital outpatient or clinic settings (Place of Service 19 or 11).
Clinical & Coding Specifications
Clinical Context
A patient with known non–muscle-invasive bladder cancer scheduled for intravesical therapy with Bacillus Calmette-Guérin (BCG). The patient arrives to a hospital outpatient department (POS 19) or clinic (POS 11) for same‑day intravesical instillation. After verification of identity, indications and consent, a bladder catheter may be placed, the urinary bladder drained, and the prepared dose of BCG (HCPCS Level II code J9030, 1 mg) instilled intravesically. The patient is monitored briefly for immediate adverse reactions, allowed to retain the instillate per protocol, then voids and is discharged with post‑instillation instructions. Documentation includes diagnosis linkage (for example D09.0 or C67.9), drug administration details (lot number, dose, lot/discard if applicable), route (intravesical), and any modifier usage (for instance JW when part of the drug is discarded).
Coding Specifications
-
HCPCS Level II code: Always reported as HCPCS Level II code
J9030for BCG live intravesical instillation, 1 mg. -
Common modifiers and use cases:
-
JW— Drug amount discarded/not administered to any patient. Use when a portion of the single‑use vial or dose is prepared but partially discarded; document the discarded amount and reason.